Efficacy and safety of bivalirudin in percutaneous coronary intervention for coronary bifurcation lesions
- Journal of Third Military Medical University Vol. 41, Issue 22, Pages: 2223-2228(2019)
- 作者机构：
400037 重庆，陆军军医大学(第三军医大学)第二附属医院全军心血管病研究所
- 作者简介：
- 基金信息：the General Program of National Natural Science Foundation of China(81670428)
DOI：10.16016/j.1000-5404.201909123
CLC： R541.4;R814.47;R973.2Received：17 September 2019，
Revised：2019-10-09，
Published：30 November 2019
- 稿件说明：
移动端阅览
Chaojun XIANG, Qi MAO, Jingdu TIAN, et al. Efficacy and safety of bivalirudin in percutaneous coronary intervention for coronary bifurcation lesions[J]. Journal of Third Military Medical University, 2019, 41(22): 2223-2228.
Chaojun XIANG, Qi MAO, Jingdu TIAN, et al. Efficacy and safety of bivalirudin in percutaneous coronary intervention for coronary bifurcation lesions[J]. Journal of Third Military Medical University, 2019, 41(22): 2223-2228. DOI： 10.16016/j.1000-5404.201909123.
摘要
目的
2
观察比伐卢定应用于冠状动脉分叉病变介入治疗中的有效性和安全性。
方法
2
本研究为回顾性队列研究，连续纳入2016年1~12月于本所经冠脉造影明确的329例冠脉分叉病变介入治疗患者。按照抗凝方式不同分为肝素组(178例)和比伐卢定组(151例)。统计两组患者的临床资料特征(性别、年龄、危险因素等)与冠脉病变情况，并随访两组患者PCI术后24 h、7 d、1年的主要不良心血管事件(major adverse cardiovascular events
MACE)及出血发生事件，其中MACE包括:死亡、心肌梗死、靶血管再次血管重建、脑卒中，而出血事件参照BARC出血分级标准进行评估。
结果
2
两组患者在人口学资料、既往病史、ACS比例、重要实验室指标和药物治疗方面基线数据差异无统计学意义。在分叉病变特征方面，两组患者的分叉病变位置、分叉病变类型、真分叉比例、主支及分支血管的长度和直径差异均无统计学意义。在PCI术后24 h内及1周内，两组均无MACE发生；肝素组有3例患者出现出血事件，无主要出血事件发生；比伐卢定组有5例患者出现出血事件，主要出血事件1例；两组间差异无统计学意义(
P
=0.477，
P
=0.459)。随访12个月后，肝素组有20例患者出现MACE，比伐卢定组有15例患者出现MACE，多因素分析显示比伐卢定对分叉病变冠脉介入治疗术后的MACE较肝素组无明显差异(
HR
=0.839，95%
CI
:0.420~1.676，
P
=0.619)。随访12个月后，肝素组有49例患者出现出血事件，主要出血事件6例；比伐卢定组有27例患者出现出血事件，主要出血事件3例；多因素分析显示比伐卢定较肝素显著减少分叉病变介入术后患者出血事件的风险(
HR
=0.557，95%
CI
:0.355~0.937，
P
=0.026)；而在主要出血事件风险方面，两者间无明显差异(
HR
=0.535
95%
CI
:0.130~2.206，
P
=0.387)。
结论
2
对冠状动脉分叉病变介入治疗患者随访12个月，比伐卢定较普通肝素显著降低出血风险，而并不增加MACE发生率。
Abstract
Objective
2
To investigate the efficacy and safety of bivalirudin in percutaneous coronary intervention (PCI) for coronary bifurcation lesions.
Methods
2
This retrospective cohort study was conducted among 329 consecutive patients with coronary artery bifurcation lesions confirmed by coronary angiography and underwent PCI in our institute between January
2016 and December
2016. All the patients received anticoagulation treatment with bivalirudin (151 cases) or heparin (178 cases). The demographic and clinical data of the patients (including gender
age
and risk factors) and the conditions of the coronary artery lesions were compared between the 2 groups. In 24 h
7 d and 12 months after the procedure
the incidences of main adverse cardiovascular events (MACE
including death
myocardial infarction
revascularization of the target vessel
and stroke) and bleeding were recorded after PCI. The bleeding endpoint was assessed in line with the BARC criteria for grading bleeding.
Results
2
No significant differences were
found between the 2 groups in the baseline data (including the demographic data
medical history
proportion of acute coronary syndrome
important laboratory indicators
and drug treatment)
nor in the characteristics of bifurcation lesions (including the lesion position
lesion type
true bifurcation ratio
length and diameter of the main branches and the branch vessels). In 24 h and 1 week after PCI
no MACE occurred in both groups. Bleeding and observed in 3 cases of the heparin group
but no major bleeding event was seen. In the bivalirudin group
there were 5 cases experiencing bleeding and 1 having major bleeding event. But no significant differonce was seen between the 2 groups (
P
=0.447
P
=0.459). Within 12 months after PCI
MACE occurred in 20 patients in the heparin group and in 15 patients in the bivalirudin group. Multivariate analysis showed that bivalirudin did not significantly affect the incidence of MACE after PCI compared with heparin (
HR
=0.839
95%
CI
: 0.420-1.676
P
=0.619). During the 12-month follow-up
49 patients in the heparin group had bleeding events (including major bleeding events in 6 patients)
as compared with 27 patients in the bivalirudin group (including 3 major bleeding events). Multivariate analysis further showed that compared with heparin
bivalirudin significantly reduced the risk of bleeding events in patients with bifurcation lesions after PCI (
HR
=0.557
95%
CI
: 0.355-0.937
P
=0.026)
but did not significantly affect the risk of major bleeding events (
HR
=0.535
95%
CI
: 0.130-2.206
P
=0.387).
Conclusion
2
In patients undergoing PCI for coronary bifurcation lesions
anticoagulation therapy with bivalirudin significantly reduces the risk of bleeding as compared with unfractionated heparin without increasing the incidences of MACE at 12 months after PCI.
关键词
Keywords
references
LASSEN J F, BURZOTTA F, BANNING A P, et al . Percutaneous coronary intervention for the left main stem and other bifurcation lesions: 12th consensus document from the European Bifurcation Club[J ] . Euro Intervention, 2018, 13(13): 1540-1553. DOI: 10.4244/EIJ-D-17-00622.
LASSEN J F, HOLM N R, BANNING A, et al . Percutaneous coronary intervention for coronary bifurcation disease: 11th consensus document from the European Bifurcation Club[J ] . EuroIntervention, 2016, 12(1): 38-46. DOI: 10.4244/EIJV12I1A7.
BANNING A P, LASSEN J F, BURZOTTA F, et al . Percutaneous coronary intervention for obstructive bifurcation lesions: the 14th consensus document from the European Bifurcation Club[J ] . EuroIntervention, 2019, 15(1): 90-98. DOI: 10.4244/EIJ-D-19-00144.
QADERDAN K, VOS G A, MCANDREW T, et al . Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials[J ] . Am Heart J, 2017, 194: 73-82. DOI: 10.1016/j.ahj.2017.08.009.
SANBORN T A, TOMEY M I, MEHRAN R, et al . Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: results from the HORIZONS-AMI trial[J ] . Catheter Cardiovasc Interv, 2015, 85(3): 371-379. DOI: 10.1002/ccd.25663.
GUERCHICOFF A, STONE G W, MEHRAN R, et al . Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute ST-segment elevation myocardial infarction: results of the HORIZONS-AMI trial[J ] . Catheter Cardiovasc Interv, 2015, 85(3): 335-342. DOI: 10.1002/ccd.25620.
STONE G W, MEHRAN R, GOLDSTEI N P, et al . Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials[J ] . J Am Coll Cardiol, 2015, 65(1): 27-38. DOI: 10.1016/j.jacc.2014.10.029.
PATEL H, GARRIS R, BHUTANI S, et al . Bivalirudin versus heparin during percutaneous coronary intervention in patients with acute myocardial infarction[J ] . Cardiol Res, 2019, 10(5): 278-284. DOI: 10.14740/cr921.
[BHOGAL S, MUKHERJEE D, BAGAI J, et al . Bivalirudin versus heparin during intervention in acute coronary syndrome: A systematic review of randomized trials[J ] . Cardiovasc Hematol Disord Drug Targets, 2019. DOI: 10.2174/1871529X19666190626124057.[Epubaheadofprint http://dx.doi.org/10.2174/1871529X19666190626124057.[Epubaheadofprint ] .
COHEN D J, BAKHAI A, SHI C X, et al . Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the sirolimus-eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions (SIRIUS) trial[J ] . Circulation, 2004, 110(5): 508-514. DOI: 10.1161/01.CIR.0000136821.99814.43.
OLMEDO W, VILLABLANCA P A, SANINA C, et al . Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: A systematic review and meta-analysis[J ] . Vascular, 2019, 27(1): 78-89. DOI: 10.1177/1708538118807522.
NDREPEPA G, NEUMANN F J, DELIARGYRIS E N, et al . Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials[J ] . Circ Cardiovasc Interv, 2012, 5(5): 705-712. DOI: 10.1161/CIRCINTERVENTIONS.112.972869.
NIKOLSKY E, MEHRAN R, DANGAS G D, et al . Cerebrovascular events after a primary percutaneous coronary intervention strategy for acute ST-segment-elevation myocardial infarction: analysis from the HORIZONS-AMI trial[J ] . Circ Cardiovasc Interv, 2015, 8(4): e002283. DOI: 10.1161/CIRCINTERVENTIONS.114.002283.
MADHAVAN M V, GÉNÉREUX P, KIRTANE A J, et al . Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial[J ] . Eur Heart J Acute Cardiovasc Care, 2017, 6(7): 650-658. DOI: 10.1177/2048872615592246.
BRENER S J, MEHRAN R, LANSKY A J, et al . Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials[J ] . Eur Heart J Acute Cardiovasc Care, 2016, 5(5): 449-454. DOI: 10.1177/2048872615624848.
VENETSANOS D, LAWESSON S S, JAMES S, et al . Bivalirudin versus heparin with primarypercutaneous coronary intervention[J ] . Am Heart J, 2018, 201: 9-16. DOI: 10.1016/j.ahj.2018.03.014.
SOUZA C F, DOIH, MINTZ G S, et al . Morphological changes and clinical impact of unstable plaques within untreated segments of acute myocardial infarction patients during a 3-year follow-up: an analysis from the HORIZONS-AMI trial[J ] . Coron Artery Dis, 2015, 26(6): 469-475. DOI: 10.1097/MCA.0000000000000251.
WARREN J, MEHRAN R, BABER U, et al . Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: insights from the harmonizing outcomes with revascularization and stents in acute myocardial infarction (HORIZONS-AMI) and acute catheterization and urgent intervention triage strategy (ACUITY) trials[J ] . Am Heart J, 2016, 171(1): 40-47. DOI: 10.1016/j.ahj.2015.07.001.
KIRTANE A J, SANDHU P, MEHRAN R, et al . Association between intraprocedural thrombotic events and adverse outcomes after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (a harmonizing outcomes with revascularization and stents in acute myocardial infarction [HORIZONS-AMI ] Substudy)[J ] . Am J Cardiol, 2014, 113(1): 36-43.DOI: 10.1016/j.amjcard.2013.08.034.
IBANEZ B, JAMES S, AGEWALL S, et al . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J ] . Rev Esp Cardiol (Engl Ed), 2017, 70(12): 1082.DOI: 10.1016/j.rec.2017.11.010.
0
Views
0
下载量
0
CSCD
- L-PDFDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
